+++ 821.675 Pressemeldungen +++ 33.979 Newsrooms +++ 6.000 Medien +++

Capsulution Nanoscience AG – Further Fundamental Patent Grant is Imminent

(PresseBox) (Berlin, ) Following a recent notice from the European Patent Office, Berlin-based Capsulution Nanoscience AG can announce that a further fundamental patent grant for its innovative nano- and microencapsulation technology – known as the LBL-Technology® – is imminent.

The patent with the number EP 1064087 covers the manufacture of multifunctional nano- and micron-sized capsules. The tiny capsules can be filled with pharmaceutical drug compounds as well as with other active substances. On the basis of the LBL-Technology® Capsulution develops advanced drug delivery systems, which bring drugs more safely and effectively to the right site of the body.

“This patent grant will secure the sustainability and the defence of our competitive advantage in the field as one of the leading developers of nano- and microcapsules intended for life science applications,” said Dr. Andreas Voigt, Chief Scientific Officer of Capsulution Nanoscience. “Finally, we can support our industrial clients, who demand for highly differentiated products in the market, which can be sustained over a long period of time.”

The LBL-Technology® represents a versatile encapsulation system. For the actual encapsulation, a wide range of FDA-approved polymers can be used. In addition, the capsules’ surface can be functionalized to suit a targeted release in the human body.

Broad field of applications:
Capsulution’s LBL-Technology® platform will soon be used for a wide range of applications. LBL-Solv® is a means of drug reformulation, where water insoluble active compounds are nanoencapsulated to increase their bioavailability. In addition, LBL-Intra is an application specific to intracellular drug delivery. The capsules may also be applied to improve the function of drug-releasing implants as well as to aid the development of nanodiagnostics.

Über die Capsulution Pharma AG

Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company implements its worldwide-patented LBL Technology®. Based on their minute size, their functionality and their highly reproducible production process, the tunable capsules can be used in a multitude of different applications. Accordingly, the precision-sized capsules can be made to function in a manner suited to the intended application, and can be given biochemical, electrical, optical and magnetic properties tailored to the individual customer. In order to meet customers’ needs for complete product solutions, Capsulution designated EBARA Corp. as the preferred developer, manufacturer and distributor for automated LBL units. In 2005, the renowned growth consultants Frost & Sullivan awarded the year’s “Product Differentiation Innovation Award” in the global nanobiotechnology market to Capsulution NanoScience AG, Berlin. The company received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.

Diese Pressemitteilungen könnten Sie auch interessieren

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.